Ahmed K - Search Results

1

CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z. Brown MS, et al. Among authors: ahmed k. Clin Cancer Res. 2010 Apr 15;16(8):2295-307. doi: 10.1158/1078-0432.CCR-09-3200. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371694 Free PMC article.

2

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Slaton JW, et al. Among authors: ahmed k. Mol Cancer Res. 2004 Dec;2(12):712-21. Mol Cancer Res. 2004. PMID: 15634760

3

Targeting CK2 for cancer therapy.

Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Ahmad KA, et al. Among authors: ahmed k. Anticancer Drugs. 2005 Nov;16(10):1037-43. doi: 10.1097/00001813-200511000-00001. Anticancer Drugs. 2005. PMID: 16222144 Review.

4

Emergence of protein kinase CK2 as a key target in cancer therapy.

Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K. Trembley JH, et al. Among authors: ahmed k. Biofactors. 2010 May-Jun;36(3):187-95. doi: 10.1002/biof.96. Biofactors. 2010. PMID: 20533398 Free PMC article. Review.

5

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K. Trembley JH, et al. Among authors: ahmed k. Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12. Cancer Lett. 2012. PMID: 22050909 Free PMC article.

6

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K. Unger GM, et al. Among authors: ahmed k. Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27. Mol Cancer Ther. 2014. PMID: 24867250 Free PMC article.

7

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K. Trembley JH, et al. Among authors: ahmed k. Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15. Mol Cell Biochem. 2011. PMID: 21761204 Free PMC article.

8

Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy.

Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Wang G, et al. Among authors: ahmed k. Mol Cell Biochem. 2005 Jun;274(1-2):77-84. doi: 10.1007/s11010-005-3077-1. Mol Cell Biochem. 2005. PMID: 16342410

9

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K. Trembley JH, et al. Among authors: ahmed k. PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014. PLoS One. 2014. PMID: 25333839 Free PMC article.

10

CK2 signaling in androgen-dependent and -independent prostate cancer.

Wang G, Ahmad KA, Unger G, Slaton JW, Ahmed K. Wang G, et al. Among authors: ahmed k. J Cell Biochem. 2006 Oct 1;99(2):382-91. doi: 10.1002/jcb.20847. J Cell Biochem. 2006. PMID: 16598768 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,736 results

Search Page

Filters